Several biosimilar news items are of note this week, including an official move by our northern neighbor to streamline its biosimilar clinical trial requirements, a new collaboration between biosimilar makers on a Keytruda biosimilar, and a new FDA approval broadening the pediatric indications for one ustekinumab biosimilar product. Health Canada’s Draft Guidance: Phase 3 Trials … Continue reading Biosimilar Bytes